J&J exhibited additional findings, displaying that nipocalimab met its key secondary endpoint, a change in QMG score.

AstraZeneca recently announced positive toplined interim results from SERENA-6, a randomised, multicentre, double-blind Phase ...

Apnimed has dosed the first subject in the Phase IIA RESTEADY trial of SASS-001, an oral drug combo for sleep apnoea with a ...

US President Donald Trump told reporters last week that pharma tariffs are coming “sometime in the near future”.

The UK Government has announced a £600m ($764m) funding pot to create a new Health Data Research Service, reducing red tape ...

The FDA has granted clearance to CureVac's IND for the open-label Phase I trial of CVHNLC in individuals with sqNSCLC.

Lipella Pharmaceuticals has concluded subject enrolment in its Phase IIa trial of LP-310, aimed at treating oral lichen planus (OLP).

If approved, LMTX has the potential to become the first orally available disease-modifying therapy (DMT) in the UK.

Sonnet BioTherapeutics has reported positive safety outcomes from a trial of SON-1010 with atezolizumab for solid tumours or ...

Johnson & Johnson has reported positive results from a Phase IIIb trial of Tremfya (guselkumab) for active psoriatic ...

Blarcamesine is a sigma 1 receptor agonist which targets Alzheimer's pathology upstream of amyloid and tau pathology.

Rhythm's Imcivree has shown benefit in a Phase III trial in patients with acquired hypothalamic obesity, leading to 19.8% ...